

Remarks/Arguments


Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies, for example by providing singly dependent versions of original multiply dependent claims, and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100864 US-1.

Respectfully submitted,



Name:	Lucy Clare Padget
Dated:	April 8, 2005
Reg. No.:	Limited Recognition CFR §11.9(b)
Phone No.:	781 839 4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham, MA 02451